AAA's cancer candidate Lutathera starts PhIII
This article was originally published in Scrip
Executive Summary
French diagnostic/therapeutic company Advanced Accelerator Applications (AAA) has pushed its investigational cancer candidate Lutathera (177Lu-DOTA-Octreotate) into Phase III trials, after earlier clinical work suggesting that the drug can extend life expectancy by 3.5 years in a subset of gastro-entero pancreatic neuroendocrine tumour types.